Dimerix

Dimerix Rule of 40

The Rule of 40 of Dimerix (DXB.AX) as of Oct 11, 2026 is -607.86 %. In the previous year, Rule of 40 was -2,781.63 % — a change of -78.15% (higher).

Rule of 40

-607.86 %

YoY

-78.15%

Last updated:

Rule of 40 of Dimerix is 2026 -607.86 % . Rule of 40 of Dimerix was 2025 -2,781.63 % . It decreases by -78.15% higher compared to the previous year.

The Dimerix Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
-228.33 AUD
Jan 1, 2020
-233.73 AUD
Jan 1, 2021
-156.46 AUD
Jan 1, 2022
-116.79 AUD
Jan 1, 2023
-62,140.37 AUD
Jan 1, 2024
-2,838.97 AUD
Jan 1, 2025
-2,781.63 AUD
Jan 1, 2026
-607.86 AUD
The Dimerix Rule of 40 history
YEARRule of 40YoY
-607.86 %-78.15%
-2,781.63 %-2.02%
-2,838.97 %-95.43%
-62,140.37 %+53,106.44%
-116.79 %-25.36%
-156.46 %-33.06%
-233.73 %+2.36%
-228.33 %-48.14%
-440.32 %+3.32%
-426.16 %+177.92%
-153.34 %-39.29%
-252.57 %—
Access this data via the Eulerpool API
Get Free API Key

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Rule of 40 of Dimerix is -607.86 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Dimerix since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API
Get Free API Key

Quality — Dimerix

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Dimerix